You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 07/28/2014

Company Name Symbol %Change
UNITED INSUR UIHC
7.03%
QIHOO 360 TE QIHU
5.15%
KB FINANCIAL KB
5.14%
VASCO DATA S VDSI
4.58%
ACADIA HEALT ACHC
3.88%
Cabot's board approves dividend of USD0.20 per share

Print Share

Jan 16, 2013 (M2 EQUITYBITES via COMTEX) -- The board of directors of Cabot Corporation (NYSE:CBT), a specialty chemicals and performance materials company, approved a quarterly common dividend of USD0.20 per share on all outstanding shares of its stock, the company declared on Tuesday.

The dividend to stockholders of record at the close of business on 1 March 2013, will be paid on 15 March 2013.

Comments on this story may be sent to info@m2.com

(C)1994-2013 M2 COMMUNICATIONS http://www.m2.com

**********************************************************************

As of Saturday, 01-12-2013 23:59, the latest Comtex SmarTrendA? Alert,
an automated pattern recognition system, indicated a DOWNTREND on
05-15-2012 for CBT @ $40.55.

For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright A? 2004-2013 Comtex News Network, Inc. All rights reserved.

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.